Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
MEDP

MEDP - Medpace Holdings Inc Stock Price, Fair Value and News

$345.15+3.33 (+0.97%)
Delayed as of 22 Nov 2024, 11:56 am ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MEDP Price Action

Last 7 days

2.1%


Last 30 days

4.7%


Last 90 days

-12.5%


Trailing 12 Months

23.5%

MEDP RSI Chart

MEDP Valuation

Market Cap

10.6B

Price/Earnings (Trailing)

29.05

Price/Sales (Trailing)

5.13

EV/EBITDA

21.68

Price/Free Cashflow

19.83

MEDP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MEDP Fundamentals

MEDP Revenue

Revenue (TTM)

2.1B

Rev. Growth (Yr)

8.29%

Rev. Growth (Qtr)

0.99%

MEDP Earnings

Earnings (TTM)

365.7M

Earnings Growth (Yr)

36.68%

Earnings Growth (Qtr)

9.14%

MEDP Profitability

EBT Margin

20.90%

Return on Equity

41.49%

Return on Assets

17.55%

Free Cashflow Yield

5.04%

MEDP Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

11.42

MEDP Alerts

  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0B2.0B2.1B0
20231.6B1.7B1.8B1.9B
20221.2B1.3B1.4B1.5B
2021955.0M1.0B1.1B1.1B
2020891.1M882.0M896.1M925.9M
2019742.3M786.2M823.2M861.0M
2018492.6M556.5M625.2M704.6M
2017428.6M428.9M431.7M436.2M
2016374.7M390.3M406.0M421.6M
2015000359.1M
20140000
MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
 CEO
 WEBSITEmedpace.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES5600

Medpace Holdings Inc Frequently Asked Questions


What is the ticker symbol for Medpace Holdings Inc? What does MEDP stand for in stocks?

MEDP is the stock ticker symbol of Medpace Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medpace Holdings Inc (MEDP)?

As of Thu Nov 21 2024, market cap of Medpace Holdings Inc is 10.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEDP stock?

You can check MEDP's fair value in chart for subscribers.

Is Medpace Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MEDP is over valued or under valued. Whether Medpace Holdings Inc is cheap or expensive depends on the assumptions which impact Medpace Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEDP.

What is Medpace Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, MEDP's PE ratio (Price to Earnings) is 29.05 and Price to Sales (PS) ratio is 5.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEDP PE ratio will change depending on the future growth rate expectations of investors.